| Species |
Human/Cynomolgus/Rhesus macaque |
| Protein Construction |
| Avi |
His |
CD28 (Asn19-Pro152)
Accession # P10747-1 |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CD28, His & Avi, Human/Cynomolgus/Rhesus macaque at 2 μg/ml (100 μl/Well) on the plate can bind AntiCD28 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
18.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 36-52 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD28 is the receptor for CD80 (B7-1) and CD86 (B7-2) proteins. When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen presenting cells (APCs). The CD86 expression on antigen presenting cells is constitutive. CD28 is the only B7 receptor constitutively expressed on naive T cells. |
| Synonyms |
CD28 antigen (Tp44); CD28 molecule; CD28; MGC138290 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
